Clinical and Experimental Developments
Buch, Englisch, 141 Seiten, Format (B × H): 155 mm x 235 mm, Gewicht: 254 g
ISBN: 978-3-540-52835-7
Verlag: Springer Berlin Heidelberg
Advanced renal cell carcinoma is refractory to nearly forms
of systemic therapy. For this reason the last decade has
seen numerous research groups working on immunotherapeutic s
trategies against it. Immunotherapy of Renal Cell Carcinoma
reports the contributions of most of the world's leading re-
search groups to two international conferences on the immu-
nobiology of this illness. Sixteen chapters divided in expe-
rimental and clinical studies provide an overview of immuno-
therapy in renal cell carcinoma and a discussion of new la-
boratory approaches to this topic.
Zielgruppe
Research
Weitere Infos & Material
Experimental Data.- Considerations in Immunotherapy of Genitourinary Neoplasia.- Murine Renal Cancer (Renca) Model: Background and Preclinical Studies.- Renal Cell Carcinoma: Experimental Metastases.- Oncogenes in Renal Cell Carcinoma.- Molecular Basis and Clinical Relevance of MDR1 Gene Expression in Renal Cell Carcinoma.- Radioimmunoconjugates in Renal Cell Carcinoma.- Interferon and Tumor Necrosis Factor in Renal Cell Carcinoma Model Systems.- Clinical Experience with Biological Response Modifiers in Renal Cell Carcinoma.- Rationale for Immunotherapy in Renal Cell Carcinoma.- Treatment of Renal Cell Carcinoma with Interferon.- Combination Therapy with Interferon in Renal Cell Carcinoma.- Recombinant Interferon Alpha Plus Vinblastine in Metastatic Renal Cell Cancer: Updated Results.- Monotherapy and Combination Therapy with Interferon-?, Interferon-?, and Tumor Necrosis Factor-? in Metastatic Renal Cell Carcinoma.- Treatment of Advanced Renal Cell Carcinoma by Systemic Low-Dose Recombinant Interleukin-2.- Direct Lymphatic Immunotherapy for Metastatic Renal Cell Carcinoma.- Combination Therapy of Renal Cell Carcinoma with Interleukin-2 and Interferon Alpha: The Cleveland Clinic Experience.- Tumor Infiltrating Lymphocytes in Human Renal Cell Carcinoma: Adoptive Immunotherapy and Characterization of Interleukin-2 Expanded Tumor-Infiltrating Lymphocytes.- Active Specific Immunotherapy in Renal Cell Carcinoma: Optimization.
